The efficacy and adverse effects of budesonide in remission induction treatment of autoimmune hepatitis: a retrospective study.

CONCLUSIONS: This study showed no differences in biochemical response between the groups. Lower, although not significantly, rate of adverse effects and lower total number of adverse effects indicate that BUD/AZA may potentially be used as the first-line treatment of choice, especially in patients with obesity, diabetes, resistant hypertension, glaucoma, or osteoporosis. PMID: 31483120 [PubMed - in process]
Source: Croatian Medical Journal - Category: General Medicine Authors: Tags: Croat Med J Source Type: research